Title: 047 Slide Show

[Image: Normal course of CMV infection]
Credits: Normal CMV Infection Time Course; by Roback JD and Josephson CD; 2013; source http://onlinelibrary.wiley.com/doi/10.1111/trf.12366/abstract; licence C

This image shows how CMV can be transmitted through transfusion. There is an early "Window Period" where CMV is in plasma and can be transmitted despite leukoreduction OR negative CMV serology. Image used with permission from Dr. Roback and Wiley Publishing.

[Image: Routine approaches to TT-CMV prevention]
Credits: Routine Approaches to TT-CMV Prevention; by Roback JD and Josephson CD; 2013; source http://onlinelibrary.wiley.com/doi/10.1111/trf.12366/abstract; licence C

This image shows how both the serology and leukocyte reduction strategies have potential "holes" where CMV might slip through. Note the overlapping "blind spot" for both strategies during the "window period" before seroconversion. Image used with permission from Dr. Roback and Wiley Publishing.

[Image: Novel approaches to TT-CMV prevention]
Credits: Novel approaches to prevent TT-CMV; by Roback JD and Josephson CD; 2013; source http://onlinelibrary.wiley.com/doi/10.1111/trf.12366/abstract; licence C

This slide shows two of the novel approaches Dr. Roback describes in this interview. The first, the "Ziemann approach," suggests that using leukoreduced components from donors who have been CMV-POSITIVE for at least a year might be the safest approach. The second, the use of CMV Nucleic Acid Testing (NAT), also shows some potential "blind spots" for CMV prevention. Neither strategy is in routine use in the U.S. Image used with permission from Dr. Roback and Wiley Publishing.